High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease  by Hedegaard, Ditte L. et al.
Research ArticleHigh resolution sequencing of hepatitis C virus reveals limited
intra-hepatic compartmentalization in end-stage liver disease
Ditte L. Hedegaard1,y, Damien C. Tully2,y, Ian A. Rowe1,–, Gary M. Reynolds3, David J. Bean2, Ke Hu1,
Christopher Davis1, Annika Wilhelm3, Colin B. Ogilvie2, Karen A. Power2, Alexander W. Tarr4,
Deirdre Kelly5, Todd M. Allen2, Peter Balfe1,⇑,, Jane A. McKeating1,3,6,
1Centre for Human Virology, University of Birmingham, Birmingham, UK; 2Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA;
3NIHR Birmingham Liver Biomedical Research Unit, University of Birmingham, UK; 4School of Life Sciences, Faculty of Medicine and Health
Sciences, University of Nottingham, Nottingham, UK; 5Liver Unit, Birmingham Childrens’ Hospital, Birmingham, UK; 6Institute for Advanced
Study, Technische Universität München, Lichtenbergstrasse 2a, D-85748 Garching, GermanyBackground & Aims: The high replication and mutation rate of Lay summary: HCV is an RNA virus that exists as a quasispecies
hepatitis C virus (HCV) results in a heterogeneous population of of closely related genomes that are under continuous selection by
viral sequences in vivo. HCV replicates in the liver and infected
hepatocytes occur as foci surrounded by uninfected cells that
may promote compartmentalization of viral variants. Given
recent reports showing interferon stimulated gene (ISG) expres-
sion in chronic hepatitis C, we hypothesized that local interferon
responses may limit HCV replication and evolution.
Methods: To investigate the spatial influence of liver architecture
on viral replication we measured HCV RNA and ISG mRNA from
each of the 8 Couinaud segments of the liver from 21 patients
undergoing liver transplant.
Results: HCV RNA and ISG mRNA levels were comparable across
all sites from an individual liver but showed up to 500-fold
difference between patients. Importantly, there was no
association between ISG and HCV RNA expression across all sites
in the liver or plasma. Deep sequencing of HCV RNA isolated
from the 8 hepatic sites from two subjects showed a similar
distribution of viral quasispecies across the liver and uniform
sequence diversity. Single genome amplification of HCV
E1E2-envelope clones from 6 selected patients at 2 hepatic sites
supported these data and showed no evidence for HCV
compartmentalization.
Conclusions:We found no differences between the hepatic and
plasma viral quasispecies in all patients sampled. We conclude
that in end-stage liver disease HCV RNA levels and the genetic
pool of HCV envelope sequences are indistinguishable between
distant sites in the liver and plasma, arguing against viral
compartmentalization.Journal of Hepatology 20
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therapy. The primary site of HCV replication is the liver and yet
our understanding of the spatial distribution of viral variants
within the liver is limited. High resolution sequencing of HCV
and monitoring of innate immune responses at multiple sites
across the liver identified a uniform pattern of diversity and
argues against viral compartmentalization.
 2016 European Association for the Study of the Liver. Published
by Elsevier B.V. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Introduction
Hepatitis C virus (HCV) is a positive-strand enveloped RNA virus
that infects more than 180 million people worldwide, with
approximately two-thirds of individuals developing a persistent
infection. Chronic hepatitis C is characterized by a long time
course, often extending for decades, that can lead to clinical
symptoms including fibrosis, cirrhosis and hepatocellular carci-
noma (HCC). Infection is characterized by ongoing changes in
viral sequences that enable the virus to persist and evade
immune surveillance or antiviral therapies [1,2]. These ‘‘swarms”
of related viruses have been detected in the liver and peripheral
blood or plasma [3–7].
The major cell type in the liver that supports HCV infection is
the hepatocyte and recent studies suggest that 1 to 50% of cells are
infected and express viral proteins or RNA [8–11]. These infected
cells occur as clusters surrounded by uninfected hepatocytes, con-
sistent with earlier studies showing HCV dissemination via cell-
to-cell contacts [12,13]. Such isolated foci of infected hepatocytes
support a model of intra-hepatic HCV compartmentalization,
where viral variants may be localised to discrete regions of the
liver. Studies with HIV showed evidence for distinct HIV quasis-
pecies in the white pulp areas of the spleen that contribute to
the reservoir of immune escape variants [14–16]. Our recent
study showing that cell-to-cell transmission is the most efficient
route for HCV to disseminate in vitro [17] supports a model where17 vol. 66 j 28–38
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some viral strainsmay be retained in the liver and not found in the
periphery. Collectively, these studies highlight our limited under-
standing of HCV spatial genetic diversity within the liver.
Chronic hepatitis C is associated with an active interferon
(IFN) response showing high levels of IFN-stimulated gene (ISG)
messenger (m)RNAs in the infected liver [18,19]. HCV has been
reported to disrupt host innate immune defenses in vitro [re-
viewed in [20]], however the significance of these evasion strate-
gies in the infected liver are unclear. It is interesting to consider
that the clustered pattern of infected cells observed in vivo may
be explained by local IFN responses limiting viral spread. Indeed,
we previously reported that IFNs limit the infectivity of secreted
HCV particles [21]. Sheahan and colleagues reported increased
ISG mRNA in ‘uninfected’ hepatocytes that were adjacent to
HCV infected cells [22], raising questions on the role of this acti-
vated bystander response in controlling viral replication and in
imposing an immune barrier to HCV sequence diversity.
To investigate whether a spatial interplay exists between host
innate immune responses, HCV replication and genetic compart-
mentalization we measured ISG levels, HCV RNA and the compo-
sition and distribution of viral quasispecies in tissue sampled
from each of the eight Couinaud segments of the liver and in
the plasma of patients undergoing liver transplant.Ta
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Clinical samples
Liver tissue and plasma samples were obtained from 21 of 23 patients with
chronic HCV infection recruited to the ITX5061 in liver transplant recipients trial
[23]. All patients gave specific informed consent and ethical approval was given
by the UK National Research Ethics Service (reference 10/H0301/36). A summary
of the clinical characteristics and the indications for transplantation, as well as
the plasma and hepatic viral loads are detailed in Table 1. Liver tissue from
deceased individuals without diagnosed disease were included as normal con-
trols. These livers had been rejected for liver transplantation due to detectable
steatosis. On receipt of the explanted liver in the laboratory 250 mg specimens
from each of the 8 Couinaud’s segments or a single sample from the control livers
were collected for RNA extraction as soon as possible after explant (Table 1).
Briefly, snap frozen samples were added to 4 ml of ice-cold RLT buffer (Qiagen,
Germany), homogenized using a gentleMACSTM protocol (Miltenyi Biotec, UK),
RNA prepared from the homogenate in accordance with the manufacturer’s
instructions (RNAeasy Midi kit, Qiagen, Germany) and assessed for possible
degradation (Aligent 2200 Tapestation, all RNA integrity number (RIN)>7.5). Viral
RNA was purified from 5 ml of plasma (Viral RNA kit, Qiagen, Germany). Plasma
samples used in this study were taken within 12 h of the start of the surgery. The
amount of HCV in the plasma was quantified in International Units (IU)/ml and
converted to HCV copy numbers using the manufacturer’s guidelines (1 IU = 2.7
HCV copies, Cobas Amplicor 2.0 assay, Roche).
Quantitative Real Time PCR (qRT-PCR)
All cellular mRNA levels were quantified using gene-specific primers together
with a glyceraldehyde 3-phosphate dehydrogenase (GAPDH) endogenous refer-
ence gene (TaqMan Gene Expression Assays, Life Technologies, UK) in either an
ABI 7500 (96 well) or ABI 7900HT (384 well) PCR machine (Applied Biosciences)
using a Cells Direct One-Step qRT-PCR kit (Life Technologies, UK). For the detection
of HCV a 50UTR specific primer set was used (Primer Design, UK). All measure-
ments were performed in triplicate in two separate qRT-PCR runs. The quantity
of total RNA recovered from each biopsy sample was determined by spectropho-
tometry, allowing us to adjust the HCV copy numbers according to RNA yield.
Amplification of HCV structural genes for single genome amplification
HCV cDNAs for SGA were generated using primers specific for either genotype 1a
(2616a-1a: GGG ATG CTG CAT TGA GTA, where the name reflects the location
(H77 numbering), orientation (sense/antisense) and genotype specificity of theJournal of Hepatology 2017 vol. 66 j 28–38 29
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primer) or genotype 3a (3471a-3a: CAA TAG TTC CAA GAA GGC CCC TAG TTT GCT
G). cDNA was generated from 5 lg RNA using 0.4 lM antisense primers together
with Superscript III reverse transcriptase; cDNA synthesis was performed for
30 min at 55 C, followed by denaturation at 94 C for 2 min. Two-step ‘‘nested”
PCR amplifications were set-up on ice using a PhusionTM High-Fidelity DNA poly-
merase system (New England Biolabs, GC buffer) in accordance with the manu-
facturer’s instructions, with the addition of 4% dimethyl sulfoxide (DMSO) to
improve yield. The first round primers were: genotype 1 (70s: AGA AAG CGT
CTA GCC ATG GCG TTA G and 2616a-1a) or: genotype 3 (70s and 3471a-3a),
the PCR amplification conditions were: 30 (94 C, 15 s; 60 C, 15 s; 72 C,
150 s). 2 ll of the completed PCR reaction was added to a PCR mixture containing
a sense primer (166s-CAAC: CAA CGT GGT CTG CGG AAC CGG TGA GTA CAC CG)
and either a genotype 1a (2582a-1a: TTA CGC CTC CGC TTG GGA TAT GAG TAA
CAT CAT) or genotype 3a (3443a-3a: CCC CTA GTT TGC TGG GCG TAT GCT GTG
ATC G) antisense primer and re-amplified using the same conditions as in the first
PCR. The nested PCR reactions were repeated using a single genome amplification
(SGA) end-stage limit dilution procedure to recover single molecules of HCV,
cloned (pcDNATM.1D/V5-His-TOPO, Life Technologies) and sequenced, as previ-
ously described [24]. All sequences have been deposited in GenBank under acces-
sion numbers KX084541–KX084702.
Deep sequencing of HCV structural and non-structural genes
RT-PCR amplification was performed across the HCV genome using an overlap-
ping amplicon approach to generate near full-length genomes for deep sequenc-
ing. For genotype 1a, the first amplicon encompassed the structural proteins from
core to NS2 (H77: 279–3542), the second spanned from E2 to NS4B (2290–4774)
and the third from NS3 to NS5A (4656–7148). A fourth amplicon covering the
remainder of NS5A and the NS5B region failed to amplify. For genotype 3a, the
first, second and fourth amplicons were successfully amplified (279–3542,
2486–5776 and 7373–9365 (NS5A to NS5B)) whereas amplicon 3, covering the
remainder of NS4B and the 50half of NS5B, failed amplification. For each amplicon
1–200 ng of hepatic RNA (1000 HCV copies) or RNA extracted from 100 ll of
plasma (10,000 HCV copies) was used as input template. For amplicon 1, the
reaction consisted of sense (177s: CCT TGT GGT ACT GCC TGA TAG) and antisense
primers (3542a-1a: GGG YAG CAG TTG ACA CRA TCT or 3542a-3a: CTG GGT AGC
CGT AGA AAG CAC CT) at 0.4 lM, and a Superscript III RT/Platinum Taq Mix in the
manufacturers supplied First Strand Buffer (Invitrogen), with the following condi-
tions: cDNA synthesis for 30 min at 55 C followed by heat denaturation at 94 C
for 2 min, and PCR amplification conditions of 40 (94 C, 15 s; 58 C, 30 s; 68 C
240 s), with a final extension at 68 C for 10 min. For amplicons 2 and 3 from
genotype 1a, this reaction consisted of sense (A2F: AAC GTT GCG ATC TGG AAG
AC or A3F: GCT CTC ATG ACC GGC TTT AC) and antisense primers (A2R: GGA
AGC GTG GTT GTC TCA AT or A3R: AGA GAT CTC CCG CTC ATC CT) with the same
reaction reagents as before but with an adjustment to the PCR amplification con-
ditions, which were 40 (94 C, 15 s; 55 C, 30 s; 68 C 180 s), with a final exten-
sion at 68 C for 5 min. For amplicons 2 and 4 from genotype 3a the primers were
: sense (08F: TGG GAT GGG CGY TGA ART GG or 21F: ATG TGT CYG CRG CGC TAG
C) and antisense (15R: TAG TTT GGT TGG TCG TCA GG or 25R: AGT AGG AGT AGG
CAA AGC AGC) at 0.4 lM, with the same reaction reagents as before but with the
following reaction conditions; for amplicon 2: cDNA synthesis for 30 min at 55 C,
heat denaturation at 94 C for 2 min, then PCR of 40 (94 C, 15 s; 55 C, 30 s;
68 C 180 s), with a final extension at 68 C for 10 min. For amplicon 4 the PCR
conditions were 40 (94 C, 15 s; 64 C, 30 s; 68 C 180 s), with a final extension
at 68 C for 10 min. All PCR products were visualized on 1% agarose gels and puri-
fied using the PureLink Quick Gel Extraction Kit (Invitrogen).
For deep sequencing, the PCR amplicons were fragmented and barcoded using
NexteraXT DNA Library Prep Kit, as per the manufacturer’s protocol. Samples were
pooled and sequenced on an Illumina MiSeq platform, using a 2  250 bp V2
reagent kit. Paired-end reads were assembled into a HCV consensus sequence
using the VICUNA de novo assembler software [25] and finished with V-FAT
v1.0. Reads were mapped back to the consensus using Mosaik v2.1.73, and
intra-host variants called by V-Phaser v2.0 [26,27]. All reads have been deposited
to the NCBI Sequence Read Archive under the study number SRP065844.
Assessment of sample diversity
For the deep sequence alignments diversity estimates were calculated as the per-
centage of reads spanning each coordinate that differed from the patient consen-
sus sequence at a frequency greater than 1% (referred to as percent codon
diversity). For example, if 10 of the 27 codons in the hypervariable region
(HVR) exceeded this threshold (as seen for patient 1), then the diversity was cal-
culated as 10/27 = 0.3704 or 37.04% [28]. SGA-derived sequences were aligned,30 Journal of Hepatology 20genetic distances estimated and phylogenetic trees built using the CLC work-
bench package (CLC 6.9.1, CLC bio, Denmark).Statistical analysis
The viral burden and level of host gene expression was calculated for each repli-
cate. After testing for normality (D’Agostino-Pearson test), all of the measure-
ments made were assessed as logarithmic transforms. Differences between
groups were assessed by Mann–Whitney U test and correlation coefficients (r2)
determined by linear regression. p values below 0.05 were considered significant.
All statistical tests were performed using GraphPad Prism 6.0. pSVR calculations
were performed in R using the Random Forest method as previously described
[11,29]. Statistical estimates of compartmentalization were computed using the
HyPhy package (http://www.hyphy.org) including; Hudson’s nearest neighbour
statistic (Snn), which compares the genetic distance between sequences within
and between compartments independent of phylogeny (Hudson RR, Genetics
155:2011–14), Wright’s measure of population subdivision (Fst), and the Slatkin
and Madison (SM) statistic.Results
Hepatic interferon stimulated gene expression and HCV replication
Biopsies were collected from each of the eight Couinaud seg-
ments of the explanted liver obtained from 21 HCV infected sub-
jects undergoing liver transplantation (Table 1). It is well
documented that a pre-existing IFN response de-sensitizes the
liver to IFN-based therapies. Dill and colleagues screened a large
panel of ISGs and discovered three genes; ISG15, IFI27 and RSAD2
(Viperin) that identified patients with elevated endogenous IFN
responses [30]. We therefore measured ISG15, IFI27, RSAD2 and
HTATIP2 mRNA (which acts as an internal referent) levels by
qRT-PCR in all 8 biopsies sampled from the explant liver. We
observed comparable levels of ISG mRNA in all biopsies sampled
from a single liver, with limited variability (ranges: IFI27, 1.2–5.7-
fold (median 2.1); ISG15, 0.9–2.2-fold (median 1.6); RSAD2, 1.4–
3.9-fold (median 1.8)) (Fig. 1A–D). We observed large differences
in ISG mRNA levels between subjects: IFI27: 68-fold, ISG15: 37-
fold and RSAD2: 43-fold (one-way ANOVA, p <0.0001). In contrast
HTATIP2 mRNA levels only varied 3-fold among biopsies sampled
from all patients (Fig. 1D). Hepatic biopsies from deceased donors
with no diagnosed disease were used as ‘normal’ controls to mea-
sure ISG expression. The majority of HCV infected liver explants
(19/21) showed increased IFI27 mRNA levels relative to the con-
trols; whereas approximately half showed elevated ISG15 (12/21)
or RSAD2 (13/21) expression (Fig. 1A–D). Only 2 patients showed
any elevation of HTATIP2 levels. An algorithm to summarize hep-
atic ISG expression [11,29,31] was calculated and 19 of the 21
explants showed values below 0.5, consistent with a high level
of endogenous ISG expression.
Recent studies show the major IFN induced by HCV infected
hepatocytes is type III IFNk [32,33]. Amplification of IFNk mRNA
gave very low signals, with many biopsies producing no PCR pro-
duct (no amplification in 35 cycles). In those cases, where IFNk
mRNA was detectable, the levels were much lower (5000–
20,000 fold) than the IFI27, ISG15 and RSAD2 mRNAs, and similar
levels were detected in all 8 biopsies (<10-fold variation) suggest-
ing that, when present, IFNk is uniformly expressed across the
liver (data not shown). Together these data show a remarkably
uniform distribution of ISGs in biopsies sampled across multiple
segments of the liver, however, we noted a wide range of ISG
expression between subjects.17 vol. 66 j 28–38
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denotes the mean expression of normal biopsies.
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JOURNAL OF HEPATOLOGYIn parallel with monitoring ISG mRNA levels in the liver biop-
sies we measured HCV RNA. The viral RNA burden in the 8 biop-
sies from a single explant varied from 1.47–6.17-fold (median
3.19), with 7 of the 21 livers showing higher than 5-fold variation
across all sites sampled (Fig. 2A). In contrast, the viral RNA bur-
den varied by over 500-fold between patients, from 1.4 (±0.6)
to 228 (±48.1) HCV copies/ng RNA. HCV RNA levels were inde-
pendent of the infecting viral genotype or clinical diagnosis
(Table 1). We saw no evidence for any association between
intra-patient variance and HCV RNA burden (r2 = 0.07, n.s.,Journal of Hepatology 20Fig. 2C). The levels of HCV RNA detected in the plasma at the time
of the transplant varied by over 10,000-fold between patients,
ranging from 8.2  102 to 3.7  107 genomes/ml (Fig. 2B). These
large variations in plasma and liver HCV RNA led us to assess
the correlation between the viral burden in the two compart-
ments. A low but significant correlation was observed (r2 = 0.13,
p <0.0001), suggesting that plasma load is a relatively poor pre-
dictor of hepatic burden (Fig. 2D).
There was no correlation between the intra-hepatic ISG mRNA
and HCV RNA in the same biopsy or plasma load (IFI27: Pearson’s
r2 = 0.007 (p = 0.72), ISG15: r2 = 0.016 (p = 0.59), RSAD2: r2 = 0.007
(p = 0.73)). A combined multivariate analysis of ISG mRNA levels
against viral burden was similarly non-significant (r2 = 0.039, F-
ratio = 0.25, p = 0.86). In summary, we found no evidence for
hot spots of viral replication, with comparable HCV RNA loads
detected across all segments in 21 subjects that was independent
of ISG expression.
Hepatic HCV quasispecies
Recent advances with deep sequencing technologies have made
it possible to investigate the viral quasispecies in unprecedented17 vol. 66 j 28–38 31
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Fig. 3. Deep sequencing of HCV hepatic and plasma quasispecies. Linear heat map representation of amino acid diversity within the structural and non-structural
proteins for the plasma and for the 8 segment biopsies from patient 1 (A) and patient 2 (B). Each square represents a polymorphic codon, coloured to reflect the percentage
of reads that exhibit diversity. The diversity scale is colour coded with highly conserved residues in black. Low frequency polymorphisms (<10%) are in dark blue,
intermediate levels of polymorphism shade from blue (10%) to green (45%), with the most highly variant residues (45–60%) shaded from green to orange. Only codons
exhibiting diversity greater than 1% are shown.
Table 2. HCV Sequence information.
Patient 
No.
Genotype Diagnosis Number 
of SGA 
sequences
Number of detected 
polymorphisms
Mean Shannon 
entropy/nucleotide
Slatkin-Maddison 
p value (inferred 
migration events)3
dN/dS4
liver plasma consensus1 SGA (liver 
+ plasma)2
liver plasma liver + 
plasma
liver liver vs. 
plasma
liver 
E1E2
plasma 
E1E2
liver 
HVR1
plasma 
HVR1
1
3a
3a
3a C 8 9 21.7
(9.7)
160 0.021 0.028 0.028 0.44 
(1.5)
0.33
(2.5)
0.14 0.17 1.55 1.38
4 HCC 11 7 34.1
(1.7)
100 0.018 0.018 0.020 0.34
(3)
1
(7)
0.65 0.49 3.25 2.49
55 C 20 - 42.7
(12.4)
199 0.035 - - 0.76 
(3.25)
- 0.17 - 0.56 -
2 1a C 15 7 65.3 
(11.3)
204 0.032 0.017 0.031 0.25
(3)
1
(7)
0.14 0.10 2.06 ∞6
HCC 14 11 38.4 
(11.9)
209 0.030 0.023 0.031 0.02
(2)
0.22
(7)
0.15 0.21 0.16 0.30
9 C 10 7 46.7
(3.1)
125 0.029 0.031 0.032 0.88
(4)
1 
(7)
0.07 0.08 0.99 1.21
1a
1a
7
1Mean number of polymorphisms per consensus sequence (Standard Deviation); 2Total number of polymorphic sites within the sequence alignment; 3Mean p value and
inferred migration events between liver biopsies and between liver and plasma; 4dN/dS-ratio were calculated from the average dN and dS of all pairwise comparisons
between sequences; 5Patient 5 did not have any amplifiable HCV in the plasma; 6No synonymous changes were detected among the plasma derived HVR1 sequences in
patient 2. The dN value for this patient was 0.05.
Research Articledetail, allowing us to perform a comprehensive assessment of the
distribution and evolution of viral sequences across the liver.
From our earlier studies measuring hepatic ISG and HCV RNA
levels, we selected patients 1 (genotype 3) and 2 (genotype 1a)
as representative cases of the two major infecting genotypes in
our cohort. The genomes were sequenced for patient 1 (H77 posi-
tion 279–5776 and 7373–9365) and patient 2 (279–7148) using
deep sequencing (Illumina MiSeq). The mean sequence coverage
at each nucleotide position was 5894 ± 1511 (patient 1) and
7465 ± 2399 (patient 2), allowing us to detect variants in the viral
population at a frequency of <0.1% [26].
The genetic diversity among all hepatic sites in both patients
revealed a striking similarity across the structural and non-
structural regions. That is, not only were the same codons vari-
able, the total diversity was similar in all samples (Fig. 3 and
Table 3). For instance, within patient 1, there were two residues
(L144 and V162; H77 numbering) within the core protein that
were polymorphic throughout all samples. The first position32 Journal of Hepatology 20was highly diverse with alanine to valine substitutions occurring
at frequencies of 35% (segment 8) to 43% (segment 4) (Fig. 3A and
Table 3A). At the second site an isoleucine to valine polymor-
phism was observed, ranging in frequency from 18% (segment
8) to 25% (segment 3). Although a few sites differed between hep-
atic segments generally all of these sites were low frequency vari-
ants at below 5%. Similar data were obtained for patient 2, with
the same polymorphisms found across all 8 hepatic segments
(Fig. 3B and Table 3B) and only subtle differences observed with
low frequency variants. However, one unique polymorphism
(A573, NS3) was found to be restricted to a single hepatic seg-
ment (segment 5) at a frequency >10% (Fig. 3B). As expected
the majority of polymorphic sites were located in the first hyper-
variable region of E2 (HVR1) (Fig. 3 and Table 3). In patient 1, we
noted that the level of diversity in the HVR region was 5 times
higher than in the rest of E2, while in patient 2 this diversity
was 6 times greater. Although unique low frequency variants
were detected in the liver samples, no specific variants were17 vol. 66 j 28–38
Table 3. HVR polymorphism. (A) Patient 1 HVR1 polymorphisms detected by Deep Sequencing. (B) Patient 2 HVR1 polymorphisms detected by deep sequencing.
HVR1 Plasma Seg1 Seg2 Seg3 Seg4 Seg5 Seg6 Seg7 Seg8
HTYTTGSSPARGASMIASMFAPGARQN 27.3%1
(42)
32.9% 
(25)
28.4% 
(61)
26.9% 
(46)
38.0% 
(76)
41.2% 
(61)
31.7% 
(91)
44.3% 
(100)
42.9% 
(66)
..H....IAG....R...I........ 20.8% 
(32)
10.5% 
(8)
14.4% 
(31)
13.5% 
(23)
9.0% 
(18)
18.9% 
(28)
15.0% 
(43)
11.1% 
(25)
3.9%
(6)
Q.H....IA.....T...I........ 11.7% 
(18)
14.5% 
(11)
9.3% 
(20)
8.2% 
(14)
10.0% 
(20)
16.9% 
(25)
14.3% 
(41)
8.4%
(19)
9.7% 
(15)
..................I........ 11.0% 
(17)
10.5% 
(8)
5.6% 
(12)
10.5% 
(18)
8.5% 
(17)
3.4%
(5)
9.0% 
(23)
11.1% 
(25)
15.6% 
(24)
.................NI........ 6.5% 
(10)
10.5%
 (8)
10.2% 
(22)
9.9% 
(17)
9.5% 
(19)
4.7%
(7)
67.0% 
(20)
5.8%
(13)
7.8% 
(12)
.................NI.S...... 5.2%
(8)
7.9%
(6)
7.0% 
(15)
10.0% 
(17)
7.5% 
(15)
0%
(0)
3.5% 
(10)
4.9%
(11)
0%
(0)
.................GI........ 5.2%
(8)
7.9%
(6)
5.1% 
(11)
4.1%
(7)
0%
(0)
0%
(0)
4.9% 
(14)
3.5%
(8)
5.2%
(8)
Q.H....IA....NS...I........ 2.6%
(4)
2.6%
(2)
3.3%
(7)
2.3%
(4)
2.0%
(4)
4.7%
(7)
1.1%
(3)
3.1%
(7)
1.3%
(2)
..............G...I........ 2.0%
(3)
0%
(0)
3.3%
(7)
0%
(0)
2.0%
(4)
2.7%
(4)
2.1%
(6)
2.2%
(5)
1.3%
(2)
.............N....I........ 1.3%
(2)
0%
(0)
2.8%
(6)
3.5%
(6)
4.5%
(9)
1.4%
(2)
3.5% 
(10)
0%
(0)
3.3%
(5)
....................S...... 1.3%
(2)
0%
(0)
1.9%
(4)
3.5%
(6)
2.0%
(4)
0%
(0)
1.7%
(5)
3.1%
(7)
2.0%
(3)
Q.H....IA....HS...I........ 0%
(0)
0%
(0)
1.9%
(4)
1.8%
(3)
3.0%
(6)
4.7%
(6)
2.4%
(7)
0%
(0)
2.6%
(4)
Total2 94.8% 
(104)
97.4% 
(68)
93.0% 
(139)
67.3% 
(161)
96.0% 
(192)
98.4% 
(145)
96.1% 
(232)
97.4% 
(220)
95.5% 
(148)
A
HVR1 Plasma Seg1 Seg2 Seg3 Seg4 Seg5 Seg6 Seg7 Seg8
NTHVTFFSAARDVLGFRNFFTLGPRQN 88.5%1
(437)
90.9% 
(331)
85.5% 
(364)
78.6%  
(331)
81.8% 
(437)
82.9% 
(334)
87.3% 
(434)
85.4% 
(729)
83.6% 
(583)
Q.........HTAW.LTSLLAP.AK.. 0.8% 
(4)
3.3% 
(12)
2.4% 
(10)
5.5% 
(23)
3.4% 
(18)
4.0% 
(12)
2.4% 
(12)
2.7% 
(23)
5.2% 
(36)
..................L.....K.. 4.9% 
(24)
1.4%
(5)
3.1% 
(13)
3.8% 
(16)
1.7%
(9) 
4.0% 
(16)
2.4% 
(12)
1.6% 
(14)
4.2% 
(29)
.................D......K.. 3.3% 
(16)
1.1%
(4)
1.2%
(5)
2.9% 
(12)
1.1%
(6)
3.0%
 (12)
0%
(0)
1.3% 
(11)
0.3%
(2)
.............S..AK..IR..S.. 0%
(0)
0%
(0)
0%
(0)
2.1%
(9)
0.4%
(2)
0.7%
(3)
0.4%
(2)
0.7%
(6)
0.9%
(6)
S.......................... 0%
(0) 
0%
(0)
0%
(0)
0%
(0)
2.8%
(15)
0%
(0)
1.2%
(6)
0%
(0)
0%
(0)
Total2 97.5% 
(481)
96.7% 
(352)
92.2% 
(392)
92.9% 
(391)
91.2%
(487)
94.6% 
(377)
93.7% 
(466)
91.8% 
(783)
94.2% 
(656)
B
1Frequency of sequence (number of reads in brackets); 2the difference between the column total and 100% reflects the presence of sequences at a frequency of <1%, 1409 of
the 1538 HVR1 sequences (91.6%) detected in this patient are shown here; 3the difference between the column total and 100% reflects the presence of sequences at a
frequency of <1%, 4385 of the 4683 HVR1 sequences (93.6%) detected in this patient are shown here.
JOURNAL OF HEPATOLOGYenriched in any particular sample and there was no evidence for
signature sequences associated with a hepatic location (Fig. 3 and
Table 3).
To further investigate the HCV quasispecies a subset of 6
patients (3 genotype 1a, 3 genotype 3) was selected for SGA by
limit dilution PCR. The same hepatic RNA employed for deep
sequencing was used as the template for a nested PCR and SGA.
A total of 118 SGA-derived HCV E1E2 clones were obtained and
sequenced, with an average of 20 clones per patient. Surprisingly
we found no evidence for elevated polymorphism in the regionsJournal of Hepatology 20of genotype 3a E2 region previously identified as HVR2 and HVR3
[34,35], or in HVR495 and HVR575 [36].
The SGA clones allowed us to assess selection pressures by
comparing the rate of substitutions at non-synonymous sites
(dN) to the rate of substitutions at synonymous sites (dS) across
the E1E2 region. The majority of substitutions were synonymous,
with observed dN/dS ratios between 0.07 and 0.65 (Table 2). As
expected, the majority of dN changes localised to the HVR1, lead-
ing to the highest dN/dS ratios in this region (Table 2). Elevated
frequencies of dN genetic changes have previously been17 vol. 66 j 28–38 33
Research Article
associated with the innate and adaptive immune response [37].
We saw no correlation between ISG mRNA levels and the dN/dS
ratio for E1E2 or HVR1 (E1E2 r2 = 0.33 ± 0.027 p = 0.59, HVR1
r2 = 0.05 ± 0.023 p = 0.25). Taken together, deep sequencing and
SGA show similar patterns of viral genetic variation across the
liver that are independent of ISG expression during end-stage
liver disease (ESLD).
Plasma HCV quasispecies
Given the relatively poor correlation between hepatic and plasma
HCV RNA levels, we were interested to determine whether all
members of the hepatic quasispecies were represented in the
plasma. Deep sequencing of plasma HCV RNA from patients 1
and 2 showed a similar pattern of diversity to the hepatic seg-
ments (Fig. 3 and Table 3). For example, the two variable residues
(core L144 and V162) noted in the liver segments from patient 1
were present in the plasma at similar frequencies (L144: 43% vs.
40% ± 2.7; V162: 20% vs. 22% ± 2.2). Overall, the levels of codon
diversity in plasma viral RNA were similar to those measured
in the liver (core: 2.62% and 2.55% ± 0.19; E1: 5.73% and
5.14% ± 0.86; E2: 6.23% and 5.86% ± 0.20; p7: 14.28% and
11.11% ± 1.90; NS2: 4.15% and 4.09% ± 0.83; NS3: 3.01%
and 3.70% ± 0.86; NS4A: 0% and 2.32% ± 1.64; NS4B: 2.30% and
1.44% ± 1.34; NS5A: 2.44% and 3.05% ± 3.63; NS5B: 0.87% and
1.82 % ± 1.19, respectively). Within NS5B, two threonine codons
(T66 and T340) differed between the plasma and the hepatic seg-
ments. At position 66 the plasma harbours a dominant alanine
codon at this position (61%) with threonine as the minor variant
(39%). In contrast the hepatic segments contain a threonine
codon (95–99%) with the alanine only rarely seen, at a maximum
frequency of 3.8%. Similarly, at position 340 in the plasma, in
addition to the dominant threonine codon, a methionine variant
was observed at a frequency of 33%. This variant was only seen in
6 of 8 hepatic segments and at a maximum frequency of 2%. For
patient 2 concordant patterns of diversity were observed in the
plasma and hepatic segments, with similar levels of codon diver-
sity in plasma and liver samples (core: 1.05% and 0.72% ± 0.39;
E1: 1.56% and 2.02% ± 0.18; E2: 9.09% and 8.81% ± 0.66;
p7: 3.17% and 4.37% ± 1.12; NS2: 7.37% and 6.86% ± 1.51; NS3:
11.09% and 10.76% ± 1.32; NS4A: 3.70% and 1.85% ± 0; NS4B:
14.94% and 15.33% ± 2.61; NS5A: 6.29% and 3.98% ± 0.97, respec-
tively). In this patient one mutation within NS3 (T563) was not
detected in plasma but was found in hepatic segments 1,7 and
8 at a frequency of 11–13% (Fig. 3B).
Within the HVR1 we found an average of 9.7 (±0.9) amino acid
polymorphisms for patient 1 and 14.7 (±0.7) for patient 2 (con-
sidering only those sites with >1% prevalence) (Fig. 3A and
Table 3A). The heat maps reflect a diverse quasispecies within
the plasma from patient 1, with numerous polymorphisms
within HVR1 (Fig. 3 and Table 3). The two viral variants present
at greater than 10% frequency were also most prevalent in the
liver (Fig. 3 and Table 3). All plasma variants were observed in
the hepatic samples, including minority variants. A more homo-
geneous population was observed in patient 2, with only one
major variant present, constituting 73.4% of the plasma
sequences and ranging in abundance from 66.3% to 73.5% in the
liver. Several minor variants (<5%) were distributed throughout
all sites sampled with all variants shared with the plasma at some
frequency (Fig. 3B and Table 3B).
The Shannon entropy algorithm can be used to quantify the
relative frequency of the variants within a sample. We obtained34 Journal of Hepatology 20values of 0.028 (plasma) and 0.021 ± 0.007 (hepatic) for patient
1. Similar values were calculated for patient 2 of 0.017 (plasma)
and 0.032 ± 0.005 (hepatic) (Table 2), demonstrating similar
levels of polymorphism at all sites. Quantifying the selection
pressures acting on each sample revealed a high proportion of
synonymous substitutions across both structural and non-
structural regions and elevated rates of dN changes within the
HVR. This pattern was independent of the site of origin, indicat-
ing that both plasma and hepatic quasispecies were evolving in
a similar fashion (data not shown). These observations confirm
those obtained by SGA sequencing and show concordant results
independent of sequencing technology. The high dN substitution
rate implies that, even in ESLD, some viral variants may be the
result of selective host immune pressure.
Phylogenetic analysis of HCV compartmentalization
Our complete data set of HCV sequences from the liver and
plasma allows us to rigorously assess genetic compartmentaliza-
tion. A phylogenetic comparison by the neighbour joining
method of consensus or SGA-derived nucleotide sequences
showed no evidence for biopsy-specific sequences (Fig. 4A).
Although the sequences obtained from the livers of patients 2,
4 and 5 showed a few pairings, where two SGA sequences from
the same hepatic segment grouped together, these clusters
included sequences isolated from other sites within the liver.
SGA sequences from different liver biopsies were dispersed
across their phylogenetic trees, with no site-specific clustering.
In patient 7 there was weak evidence for some clustering, with
SGA sequences from segments 1 and 6 grouping together and
two SGA sequences from segment 1 grouping with their cognate
consensus sequence. This was supported statistically by the tree-
based SM test (p = 0.02, inferred migration events: 2). There was
no evidence of population structure for the other five patients
(mean p = 0.67, ±0.38, mean inferred migration events: 2.72,
±1.49) (Table 2). When we repeated this analysis using the deep
sequencing data from patients 1 and 2, we found no evidence for
intra-hepatic compartmentalization (p >0.05).
Analysis of sequences from patient plasma showed limited
evidence of compartmentalization, with similar genetic distances
among the plasma- and liver-derived sequences making it impos-
sible to map the source of the plasma sequences to any specific
location in the liver (Table 2;Fig. 4B). Examination of the liver
as a single entity also showed no evidence for HCV compartmen-
talization between plasma using either the SM test (patient 1,
p = 1; patient 2, p = 1) or two other alternative methods for
assessing population structure; Wright’s measure of population
subdivision (Fst) and Hudson’s Nearest Neighbour statistic (Snn),
(patient 1, Fst p = 0.74, Snn p = 0.79; patient 2, Fst p = 0.96, Snn
p = 0.42). Overall these data confirm the observations made using
the SGA sequences and show that even deep sequencing of the
plasma and liver segments failed to detect any major differences
between the viral quasispecies at different sites. Furthermore, the
simultaneous presence of identical HCV quasispecies variants in
the different segments of the liver supports our conclusion that
intra-hepatic compartmentalization is not a hallmark of ESLD.Discussion
The goal of this study was to assess the spatial relationship
between innate immune responses, HCV RNA burden and viral17 vol. 66 j 28–38
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Fig. 4. Phylogenetic relationships between HCV sequences in liver and plasma. The relationships between HCV E1E2 SGA sequences derived from selected hepatic
segments and plasma were assessed by neighbour joining analysis. There was minimal evidence for clustering of SGA-derived sequences originating from the same hepatic
segment. The upper phylogenetic trees denote sequences from patients 1, 4 and 5 (genotype 3) while the lower trees represent patients 2, 7 and 9 (genotype 1a). In each
tree black squares denote SGA-plasma sequences, whereas coloured circles denote SGA-hepatic sequences derived from segment 1 (green), 3 (cyan), 6 (blue) or 7 (grey). Red
triangles represent consensus nucleotide sequences obtained from each of the eight hepatic segments (A). Quantification of mean genetic distance between SGA-derived
sequences from identical or different hepatic sites and plasma (B).
JOURNAL OF HEPATOLOGYquasispecies diversity across the eight Couinaud segments of the
liver from patients undergoing liver transplant. This collection of
clinical material provides a novel insight into the relationship
between hepatic ISG expression and the viral quasispecies in
the liver and periphery.
We used the 4-gene IFN classifier developed by Dill and col-
leagues [30] to assess ISG expression in the explanted liver and
found a remarkably consistent level of expression, regardless of
the site of sampling. In contrast, we observed variable hepatic
ISG response between patients, irrespective of their diagnosis
of cirrhosis or HCC. Importantly, the ISG response across the
liver showed no correlation with HCV RNA burden in subjects
with ESLD. Using needle biopsies collected in earlier stages of
disease, other groups have also failed to observe an association
between hepatic ISG expression and HCV RNA levels
[9,30,38,39]. We conclude that in chronic late stage hepatitis C
innate IFN signaling has limited impact on HCV replication or
HCV genetic diversity.Journal of Hepatology 20The levels of HCV RNA in all eight biopsies sampled from a
single liver were surprisingly similar, suggesting that the liver
is uniformly infected during ESLD. Previous studies have shown
comparable levels of HCV RNA in biopsies sampled from up to
three different regions of a liver [40–43]. Several studies have
suggested that the frequency of HCV infected hepatocytes in
the liver is low, ranging from 5% to 20% [8,9,11,39], supporting
a model of genetic compartmentalization. Wieland and col-
leagues have suggested that infected foci comprising <5% of hep-
atocytes in the liver occur when the plasma HCV RNA burden is
<105 copies/ml and that above this threshold the frequency of
infected hepatocytes can range from 20% to 50%. In our cohort
18 of the 21 patients showed plasma HCV RNA levels well above
this threshold (Fig. 2), suggesting that ‘local’ compartmentaliza-
tion within a segment may be lost in late stage disease when
the frequency of infected cells is high. In contrast to the limited
intra-hepatic variation in HCV RNA levels we noted significant
differences between patients of up to 500-fold [11,39]. These17 vol. 66 j 28–38 35
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differences were unrelated to the patient’s age, indication for
transplantation, or infecting HCV genotype (Table 1). Although
it is possible that patients with high hepatic viral loads will have
more HCV infected cells or higher amounts of HCV RNA per
infected cell, the complex microscopic approaches to visualize
these cells using HCV core or NS5A antibodies or patient-specific
viral nucleic acids were beyond the scope of this study [8,11].
One could predict that the diversity of HCV quasispecies
would decrease in late stage disease due to a reduced immune
response, while the more active immune responses in the earlier
phases of infection may select for a greater diversity of HCV qua-
sispecies [44,45]. HCV sequence variation was readily detectable,
though it is not possible to distinguish whether this is in response
to ongoing selection or a relic of earlier evolutionary factors. We
assessed genetic polymorphism using both single gene amplifica-
tion and deep sequencing approaches. Although SGA cloning and
sequencing methods offer the advantage of identifying whole
regions of the virus, it is costly and the number of clones that
can be obtained is limited [46–49]. Deep sequencing approaches
overcome the relatively poor sampling inherent in SGA by ana-
lyzing thousands of short viral gene fragments. This allows us
to base our calculations on many hundreds of sequences and
derive our diversity estimates with complete precision. In this
study, the average number of reads for each base of the E1E2
region was 3045–11,824, which is much larger than previous
studies often with <20 sequences reported [46–49]. Interestingly
we were able to demonstrate that, even with the limited sam-
pling inherent in the method, our SGA-based inferences of
genetic diversity closely reflected those obtained from deep
sequencing. Furthermore, the sequences of our SGA clones were
the most abundant members of the quasispecies identified by
deep sequencing (Table 2), demonstrating that SGA recovers the
most representative sequences in the population.
Comparing liver-derived HCV quasispecies with plasma
showed a high degree of overlap, though the relative abundance
of the variants differed between the two compartments and a few
unique sequences were observed in each sample (Table 3). These
differences may reflect the hepatic retention of poorly released
(cell-to-cell transmitted) HCV variants [13]. Alternatively neu-
tralizing antibodies may mediate the clearance of some viruses,
leading to an over representation of neutralization escape
mutants in the periphery [3,50,51]. Extra-hepatic viral reservoirs
are another potential source of viruses in the plasma that were
not detected in the liver, a model supported by the detection of
HCV negative strand RNA in PBMCs [52,53], lymph nodes [54]
and the central nervous system [55]. These extra-hepatic sites
have been suggested to serve as reservoirs for viruses to re-
infect the allograft after transplantation [56–61].
To the best of our knowledge these data represent the most
comprehensive study on intra-hepatic HCV compartmentaliza-
tion to date using both structural and non-structural proteins.
It reveals high levels of sequence similarities between different
sites in the liver, supported by all HVR1 sequences being present
in at least 2 hepatic segments and by sub-populations of domi-
nant sequences being identical across segments. Several studies
have compared HCV sequences in the liver and plasma. Some
report a genetic relationship between viral strains present in both
compartments [3,42] with half of the patients sharing the same
consensus sequence in plasma and liver, together with a unique
site-specific set of minor sequences [3,42,50]. In contrast, Fan
and colleagues found no evidence for association between these36 Journal of Hepatology 20sites [51]. These high genetic similarities between the hepatic
segments may reflect a long history of chronic infection where
genetically distinct clusters have been lost over time.
Sobesky and colleagues [62] reported HCV compartmentaliza-
tion between tumor and non-tumor regions of the liver in 5 of 7
patients diagnosed with HCC. Consistent with these findings a
recent study by Harouaka et al. reported differences in HCV qua-
sispecies distribution between tumor and non-tumor compart-
ments [63], supporting a model where HCV may evolve
differently in non-tumor cirrhotic nodules. However, both of
these studies assessed genetic compartmentalization using the
matrix-based Mantel’s test of genetic and anatomical distances
that has been criticized for its statistical performance [64,65].
We therefore used the more rigorous SM test to evaluate com-
partmentalization, which infers the number of migration events
between compartments using the structure of the reconstructed
phylogenetic tree. While two subjects (patients 4 and 7) were
diagnosed with HCC, no evidence for E1E2 compartmentalization
was obtained. HCC was not detected in all 8 segments of these
livers, therefore our comparisons focused on non-HCC biopsies.
Many reports of HCV quasispecies genesis are based on a demic
model of viral evolution where isolated variants arise in geo-
graphically distinct locations. However, our data on HCV quasis-
pecies in the explanted liver and plasma suggest that in late stage
liver disease HCV compartmentalization does not occur.Financial support
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